Shares of Cadila Healthcare gained 4 percent intraday Thursday on the back of USFDA approval for Itraconazole capsules.
Zydus Cadila has received the final approval from the USFDA to market Itraconazole capsules, 100mg.
The drug is used to treat a variety of fungal infections and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group has now more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
At 15:24 hrs Cadila Healthcare was quoting at Rs 502.60, up Rs 16.05, or 3.30 percent on the BSE.
The share touched its 52-week high Rs 1,884.85 and 52-week low Rs 1,124.00 on 20 September, 2017 and 26 December, 2016, respectively.
Posted by Rakesh PatilDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
